Individual patient courses for all patients with ITP who received azathioprine
| ID . | Treatments received before azathioprine . | Efficacy of azathioprine . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Corticosteroids . | IVIG . | Rituximab . | Splenectomy . | TPO-RA . | Other immunosuppressive drugs . | Response achieved . | Relapse∗ . | Sustained response† . | |
| 001 | Y | Y | N | Y | N | Danazol | I | ||
| 003 | Y | Y | Y | Y | N | NR | |||
| 009 | Y | Y | Y | N | N | CR | Y | N | |
| 012 | Y | Y | N | N | N | Fostamatinib | CR | Y | N |
| 019 | Y | Y | Y | N | N | NR | |||
| 022 | Y | N | N | Y | N | CR | N | Y | |
| 025 | Y | N | N | N | N | CR | Y | Y | |
| 026 | Y | Y | N | N | N | Danazol, cyclophosphamide | NR | ||
| 027 | Y | N | N | N | N | R | N | Y | |
| 054 | Y | N | N | N | N | CR | Y | N | |
| 055 | Y | Y | N | N | N | NR | |||
| 056 | Y | Y | Y | N | N | I | |||
| 057 | Y | N | Y | N | N | NR | |||
| 058 | Y | Y | N | N | N | NR | |||
| 059 | Y | Y | N | Y | N | Danazol | I | ||
| 061 | Y | Y | N | Y | Y | CR | N | Y | |
| 063 | Y | Y | N | Y | N | CR | N | Y | |
| 066 | Y | Y | N | Y | N | CR | N | Y | |
| 068 | Y | Y | Y | Y | N | CR | N | Y | |
| 069 | Y | Y | Y | Y | N | NR | |||
| 070 | Y | Y | N | Y | N | CR | N | Y | |
| 071 | Y | Y | N | Y | Y | Hydroxychloroquine | R | N | Y |
| 072 | Y | Y | N | N | N | R | Y | N | |
| 073 | Y | Y | N | Y | N | I | |||
| 074 | Y | Y | N | N | N | CR | N | Y | |
| 075 | Y | Y | N | N | N | CR | N | Y | |
| 077 | Y | Y | N | Y | N | Danazol | I | ||
| 082 | Y | Y | Y | Y | N | NR | |||
| 084 | Y | Y | Y | Y | N | Cyclophosphamide, cyclosporine | I | ||
| 085 | Y | Y | Y | Y | N | NR | |||
| 086 | Y | Y | Y | Y | Y | CR | Y | Y | |
| 087 | Y | Y | Y | Y | Y | Mycophenolate mofetil | NR | ||
| 093 | Y | Y | N | N | N | NR | |||
| 096 | Y | Y | N | N | N | NR | |||
| 102 | Y | Y | Y | N | N | NR | |||
| 103 | Y | Y | N | N | N | CR | Y | N | |
| 105 | Y | Y | N | N | N | NR | |||
| 106 | Y | N | N | N | N | CR | Y | N | |
| 109 | Y | Y | N | N | N | NR | |||
| 110 | Y | Y | N | N | N | CR | N | Y | |
| 111 | Y | Y | N | N | N | NR | |||
| 112 | Y | N | N | N | N | NR | |||
| 113 | Y | Y | N | N | N | Hydroxychloroquine | CR | Y | N |
| 118 | Y | Y | Y | N | N | NR | |||
| 151 | Y | Y | N | N | N | I | |||
| 164 | Y | N | N | Y | N | CR | N | Y | |
| 167 | Y | N | Y | Y | N | CR | N | Y | |
| 168 | Y | N | Y | Y | N | R | N | Y | |
| 170 | Y | N | N | N | N | NR | |||
| 180 | Y | N | N | N | N | Fostamatinib | NR | ||
| 181 | Y | N | N | N | Y | I | |||
| 183 | Y | Y | N | N | N | Fostamatinib | CR | N | Y |
| 184 | Y | N | N | N | N | I | |||
| 185 | Y | N | N | N | N | CR | N | Y | |
| 186 | Y | N | N | N | N | R | N | Y | |
| 191 | Y | N | Y | N | N | Hydroxychloroquine | CR | N | Y |
| 192 | Y | N | Y | N | N | I | |||
| 255 | Y | Y | N | Y | N | I | |||
| 258 | Y | N | N | N | N | CR | N | Y | |
| 259 | Y | Y | N | N | N | Danazol | NR | ||
| 263 | Y | Y | Y | N | N | CR | N | Y | |
| 320 | Y | Y | N | N | N | R | Y | N | |
| 322 | Y | Y | N | N | N | CR | Y | N | |
| 336 | Y | Y | N | N | N | I | |||
| 342 | Y | N | N | N | N | CR | N | Y | |
| 343 | Y | N | N | N | N | CR | Y | Y | |
| 347 | Y | N | N | N | N | CR | N | Y | |
| 359 | Y | N | N | Y | N | I | |||
| 371 | Y | N | Y | Y | N | NR | |||
| 373 | Y | N | N | N | N | NR | |||
| 380 | Y | N | N | N | N | CR | N | Y | |
| 389 | Y | N | N | N | N | CR | Y | Y | |
| 395 | Y | N | N | N | N | R | Y | N | |
| 442 | Y | Y | Y | N | N | NR | |||
| 447 | Y | Y | N | N | N | NR | |||
| 465 | Y | N | N | Y | N | NR | |||
| 511 | Y | N | N | N | N | I | |||
| 528 | Y | N | N | N | N | Hydroxychloroquine | CR | N | Y |
| 535 | Y | Y | N | N | N | CR | N | Y | |
| 641 | Y | N | Y | N | N | Cyclosporine, mycophenolate mofetil | CR | N | Y |
| 647 | Y | Y | N | N | Y | NR | |||
| 652 | Y | N | N | N | N | Fostamatinib | R | N | Y |
| 656 | Y | Y | N | N | N | I | |||
| 666 | Y | N | N | Y | N | I | |||
| 670 | Y | Y | N | Y | N | NR | |||
| 673 | Y | N | N | N | N | CR | N | Y | |
| 675 | Y | Y | N | N | N | Fostamatinib | R | N | Y |
| 682 | Y | N | N | N | N | NR | |||
| 683 | Y | Y | N | N | N | I | |||
| 704 | Y | N | N | N | N | NR | |||
| 705 | Y | N | N | N | N | NR | |||
| 706 | Y | Y | N | N | N | CR | N | Y | |
| ID . | Treatments received before azathioprine . | Efficacy of azathioprine . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Corticosteroids . | IVIG . | Rituximab . | Splenectomy . | TPO-RA . | Other immunosuppressive drugs . | Response achieved . | Relapse∗ . | Sustained response† . | |
| 001 | Y | Y | N | Y | N | Danazol | I | ||
| 003 | Y | Y | Y | Y | N | NR | |||
| 009 | Y | Y | Y | N | N | CR | Y | N | |
| 012 | Y | Y | N | N | N | Fostamatinib | CR | Y | N |
| 019 | Y | Y | Y | N | N | NR | |||
| 022 | Y | N | N | Y | N | CR | N | Y | |
| 025 | Y | N | N | N | N | CR | Y | Y | |
| 026 | Y | Y | N | N | N | Danazol, cyclophosphamide | NR | ||
| 027 | Y | N | N | N | N | R | N | Y | |
| 054 | Y | N | N | N | N | CR | Y | N | |
| 055 | Y | Y | N | N | N | NR | |||
| 056 | Y | Y | Y | N | N | I | |||
| 057 | Y | N | Y | N | N | NR | |||
| 058 | Y | Y | N | N | N | NR | |||
| 059 | Y | Y | N | Y | N | Danazol | I | ||
| 061 | Y | Y | N | Y | Y | CR | N | Y | |
| 063 | Y | Y | N | Y | N | CR | N | Y | |
| 066 | Y | Y | N | Y | N | CR | N | Y | |
| 068 | Y | Y | Y | Y | N | CR | N | Y | |
| 069 | Y | Y | Y | Y | N | NR | |||
| 070 | Y | Y | N | Y | N | CR | N | Y | |
| 071 | Y | Y | N | Y | Y | Hydroxychloroquine | R | N | Y |
| 072 | Y | Y | N | N | N | R | Y | N | |
| 073 | Y | Y | N | Y | N | I | |||
| 074 | Y | Y | N | N | N | CR | N | Y | |
| 075 | Y | Y | N | N | N | CR | N | Y | |
| 077 | Y | Y | N | Y | N | Danazol | I | ||
| 082 | Y | Y | Y | Y | N | NR | |||
| 084 | Y | Y | Y | Y | N | Cyclophosphamide, cyclosporine | I | ||
| 085 | Y | Y | Y | Y | N | NR | |||
| 086 | Y | Y | Y | Y | Y | CR | Y | Y | |
| 087 | Y | Y | Y | Y | Y | Mycophenolate mofetil | NR | ||
| 093 | Y | Y | N | N | N | NR | |||
| 096 | Y | Y | N | N | N | NR | |||
| 102 | Y | Y | Y | N | N | NR | |||
| 103 | Y | Y | N | N | N | CR | Y | N | |
| 105 | Y | Y | N | N | N | NR | |||
| 106 | Y | N | N | N | N | CR | Y | N | |
| 109 | Y | Y | N | N | N | NR | |||
| 110 | Y | Y | N | N | N | CR | N | Y | |
| 111 | Y | Y | N | N | N | NR | |||
| 112 | Y | N | N | N | N | NR | |||
| 113 | Y | Y | N | N | N | Hydroxychloroquine | CR | Y | N |
| 118 | Y | Y | Y | N | N | NR | |||
| 151 | Y | Y | N | N | N | I | |||
| 164 | Y | N | N | Y | N | CR | N | Y | |
| 167 | Y | N | Y | Y | N | CR | N | Y | |
| 168 | Y | N | Y | Y | N | R | N | Y | |
| 170 | Y | N | N | N | N | NR | |||
| 180 | Y | N | N | N | N | Fostamatinib | NR | ||
| 181 | Y | N | N | N | Y | I | |||
| 183 | Y | Y | N | N | N | Fostamatinib | CR | N | Y |
| 184 | Y | N | N | N | N | I | |||
| 185 | Y | N | N | N | N | CR | N | Y | |
| 186 | Y | N | N | N | N | R | N | Y | |
| 191 | Y | N | Y | N | N | Hydroxychloroquine | CR | N | Y |
| 192 | Y | N | Y | N | N | I | |||
| 255 | Y | Y | N | Y | N | I | |||
| 258 | Y | N | N | N | N | CR | N | Y | |
| 259 | Y | Y | N | N | N | Danazol | NR | ||
| 263 | Y | Y | Y | N | N | CR | N | Y | |
| 320 | Y | Y | N | N | N | R | Y | N | |
| 322 | Y | Y | N | N | N | CR | Y | N | |
| 336 | Y | Y | N | N | N | I | |||
| 342 | Y | N | N | N | N | CR | N | Y | |
| 343 | Y | N | N | N | N | CR | Y | Y | |
| 347 | Y | N | N | N | N | CR | N | Y | |
| 359 | Y | N | N | Y | N | I | |||
| 371 | Y | N | Y | Y | N | NR | |||
| 373 | Y | N | N | N | N | NR | |||
| 380 | Y | N | N | N | N | CR | N | Y | |
| 389 | Y | N | N | N | N | CR | Y | Y | |
| 395 | Y | N | N | N | N | R | Y | N | |
| 442 | Y | Y | Y | N | N | NR | |||
| 447 | Y | Y | N | N | N | NR | |||
| 465 | Y | N | N | Y | N | NR | |||
| 511 | Y | N | N | N | N | I | |||
| 528 | Y | N | N | N | N | Hydroxychloroquine | CR | N | Y |
| 535 | Y | Y | N | N | N | CR | N | Y | |
| 641 | Y | N | Y | N | N | Cyclosporine, mycophenolate mofetil | CR | N | Y |
| 647 | Y | Y | N | N | Y | NR | |||
| 652 | Y | N | N | N | N | Fostamatinib | R | N | Y |
| 656 | Y | Y | N | N | N | I | |||
| 666 | Y | N | N | Y | N | I | |||
| 670 | Y | Y | N | Y | N | NR | |||
| 673 | Y | N | N | N | N | CR | N | Y | |
| 675 | Y | Y | N | N | N | Fostamatinib | R | N | Y |
| 682 | Y | N | N | N | N | NR | |||
| 683 | Y | Y | N | N | N | I | |||
| 704 | Y | N | N | N | N | NR | |||
| 705 | Y | N | N | N | N | NR | |||
| 706 | Y | Y | N | N | N | CR | N | Y | |
CR was defined as platelet count ≥100 × 109/L and absence of bleeding; R, platelet count ≥30 × 109/L and at least twofold increase the baseline count and absence of bleeding; NR, platelet count <30 × 109/L or less than twofold increase of baseline platelet count or bleeding. I includes patients who discontinued azathioprine before reaching a minimum of 4 weeks, which is the first time that a response to azathioprine could be reasonably expected.
I, intolerant; ID, unique study patient identification number; IVIG, IV immunoglobulin; N, no; NR, no response; R, response; Y, yes.
Patients who lost CR or R while still on azathioprine.
Patients who maintained a safe platelet count (ie, >30 × 109/L) for a minimum of 6 months after initial response.